Last reviewed · How we verify
Pregnyl (1,500) IU
Pregnyl is human chorionic gonadotropin (hCG) that mimics luteinizing hormone to stimulate gonadal hormone production and ovulation.
Pregnyl is human chorionic gonadotropin (hCG) that mimics luteinizing hormone to stimulate gonadal hormone production and ovulation. Used for Female infertility (ovulation induction, final maturation of oocytes in assisted reproductive technology), Male hypogonadism (testosterone deficiency), Cryptorchidism (undescended testis).
At a glance
| Generic name | Pregnyl (1,500) IU |
|---|---|
| Also known as | Hcg |
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | Gonadotropin; human chorionic gonadotropin (hCG) |
| Target | Luteinizing hormone receptor (LH receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Endocrinology; Fertility |
| Phase | FDA-approved |
Mechanism of action
hCG binds to luteinizing hormone receptors on Leydig cells (in males) and theca cells (in females), triggering testosterone production in males and progesterone production in females. In females, it triggers the LH surge necessary for ovulation. In males, it stimulates spermatogenesis and testosterone synthesis.
Approved indications
- Female infertility (ovulation induction, final maturation of oocytes in assisted reproductive technology)
- Male hypogonadism (testosterone deficiency)
- Cryptorchidism (undescended testis)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions (pain, redness, swelling)
- Headache
- Abdominal pain or bloating
- Nausea
Key clinical trials
- Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043) (PHASE3)
- Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration (PHASE4)
- Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor in Increasing Pregnancy Rate in ICSI (NA)
- The Effect of Granulocyte Colony Stimulating Factor Versus Human Chorionic Gonadotropin in Females With a History of RIF (NA)
- Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility (NA)
- Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility (PHASE3)
- Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis (PHASE3)
- Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregnyl (1,500) IU CI brief — competitive landscape report
- Pregnyl (1,500) IU updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI